Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future

Mo-Yun Li; Li-Ming Peng; Xiao-Ping Chen

doi:10.3389/fcvm.2022.966261

Pharmacogenomics in drug-induced cardiotoxicity: Current status and the future

Front Cardiovasc Med. 2022 Oct 13:9:966261. doi: 10.3389/fcvm.2022.966261. eCollection 2022.

Authors

Mo-Yun Li^{1

2}, Li-Ming Peng^{1

2

3}, Xiao-Ping Chen^{1

2

4}

Affiliations

¹ Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
² Hunan Key Laboratory of Pharmacogenetics, Institute of Clinical Pharmacology, Central South University, Changsha, China.
³ Department of Cardiology, Xiangya Hospital, Central South University, Changsha, China.
⁴ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China.

Abstract

Drug-induced cardiotoxicity (DICT) is an important concern of drug safety in both drug development and clinical application. The clinical manifestations of DICT include cardiomyopathy, arrhythmia, myocardial ischemia, heart failure, and a series of cardiac structural and functional changes. The occurrence of DICT has negative impacts on the life quality of the patients, brings additional social and economic burden. It is important to identify the potential factors and explore the mechanisms of DICT. Traditional cardiovascular risk factors can only partially explain the risk of DICT. Pharmacogenomic studies show accumulated evidence of genetics in DICT and suggest the potential to guide precision therapy to reduce risk of cardiotoxicity. The comprehensive application of technologies such as third-generation sequencing, human induced pluripotent stem (iPS) cells and genome editing has promoted the in-depth understanding of the functional role of susceptible genes in DICT. This paper reviewed drugs that cause DICT, the clinical manifestations and laboratory tests, as well as the related content of genetic variations associated with the risk of DICT, and further discussed the implication of new technologies in pharmacogenomics of DICT.

Keywords: biomarker; drug-induced cardiotoxicity; new technologies in pharmacogenomics; pharmacogenomics; single nucleotide polymorphisms (SNPs).

Publication types

Review